Buprenorphine and Dabrafenib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Dabrafenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Dabrafenib can make your buprenorphine work less well. Dabrafenib speeds up a liver enzyme (called CYP3A4) that breaks down buprenorphine. When buprenorphine is cleared out faster, less of it stays in your body, so you may notice your pain or cravings are not as well controlled, or you could feel withdrawal symptoms like chills, aches, sweating, or a runny nose.
There is also a second concern: both drugs can affect your heart's rhythm (called QT prolongation), and together that risk goes up. The good news is your care team can manage this by watching you closely and adjusting your buprenorphine dose as needed. Do not change anything on your own, but do talk with your doctor or pharmacist.
Mechanism: Dabrafenib is a CYP3A4 inducer; buprenorphine is a CYP3A4 substrate (active drug, not a prodrug). Induction increases buprenorphine metabolism, lowering exposure (AUC/Cmax) and risking reduced analgesia/opioid withdrawal. Both agents also prolong QT, giving additive cardiac conduction risk.
Evidence: Probable. Severity: Major. Onset: unspecified (enzyme induction is typically delayed over days).
Management:
- Monitor for withdrawal and inadequate effect; buprenorphine dose may need upward, individualized titration.
- Monitor ECG/QT, especially with other QT-prolonging factors.
- On dabrafenib discontinuation, anticipate rising buprenorphine levels; consider dose reduction and monitor for respiratory depression.
- Prefer formulations allowing precise dose adjustment when needed.
What happens
Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation
Interaction Deep Dive
Taking buprenorphine together with CYP3A4 inducers can reduce buprenorphine exposure and may bring on symptoms of opioid withdrawal. Furthermore, giving drugs that influence cardiac conduction alongside buprenorphine raises the likelihood of QT prolongation. During concurrent administration, watch the patient carefully for signs of a prolonged QT interval, think about raising the buprenorphine dose until stable drug effects are reached, and observe for withdrawal. If a CYP3A4 inducer is stopped in a patient who is on buprenorphine, consider lowering the buprenorphine dose and monitor for respiratory depression2. When the dose cannot be adjusted once the CYP3A4 inducer is gone, switch the patient back to a buprenorphine formulation that allows finer dose control. For patients who are converted from transmucosal buprenorphine given with CYP3A4 inducers, confirm through monitoring that the plasma buprenorphine level achieved by subQ buprenorphine is sufficient. In patients who are already receiving subQ buprenorphine and then need a CYP3A4 inducer, monitor for withdrawal. Should the buprenorphine dose prove inadequate while the concomitant medication is present, and that medication cannot be reduced or stopped, modify the buprenorphine dose. If the available doses do not allow the target dose to be reached, treat the patient with a buprenorphine formulation that permits more precise dose adjustments1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of buprenorphine; additive QT interval prolongation
How to manage this interaction
Keep taking both medications as prescribed unless your care team tells you otherwise. Here is what they typically do:
- Watch you for signs your buprenorphine is not working well enough, including withdrawal symptoms (aches, sweating, restlessness, cravings).
- Your buprenorphine dose may need to be adjusted and individualized by your care team until your effects are stable.
- They may check your heart rhythm (an ECG) because both drugs can affect the QT interval.
- If dabrafenib is later stopped, your team may lower your buprenorphine dose and watch for oversedation or slowed breathing.
Tell your pharmacist or prescriber if you notice returning pain, withdrawal, dizziness, fainting, or a racing/irregular heartbeat.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inducers on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, such interactions have been demonstrated in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Dabrafenib together?
Dabrafenib speeds up the breakdown of buprenorphine, so buprenorphine may work less well and cause withdrawal, and together the two can raise the risk of a heart rhythm problem (QT prolongation). Keep taking both as prescribed and let your care team adjust your dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Dabrafenib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Dabrafenib interaction managed?
Keep taking both medications as prescribed unless your care team tells you otherwise. Here is what they typically do: Watch you for signs your buprenorphine is not working well enough, including withdrawal symptoms (aches, sweating, restlessness, cravings). Your buprenorphine dose may need to be adjusted and individualized by your care team until your effects are stable. They may check your heart… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Dabrafenib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Dabrafenib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist